Get access

Lipoxin A4 Inhibits the Development of Endometriosis in Mice: The Role of Anti-Inflammation and Anti-Angiogenesis



Yinping Huang, Department of Obstetrics and Gynecology, 1st Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang 325003, China.




To evaluate the effects of the anti-inflammatory and anti-angiogenic roles of LXA4 on endometriosis in mice.

Method of study

Endometriosis was induced in 40 mice and separated into two groups. LXA4 group was administered by LXA4 for 3 weeks. The endometriotic lesions were counted, measured, and identified by pathology. The presence of a panel of pro-inflammatory factors was assessed by real-time RT-PCR, and enzyme-linked immunoassay, the mRNA, protein levels of matrix metalloproteinase (MMPs), and vascular endothelial growth factor (VEGF) were determined by real-time RT-PCR and immunohistochemistry; the activity of MMPs was evaluated by gelatin zymography.


Treatment with LXA4 significantly inhibited endometriotic lesion development (13.58 ± 4.01 mm2 in LXA4 group and 23.20 ± 7.49 mm2, = 0.0002), downregulated pro-inflammatory factors, suppressed the activity of MMP9, and reduced the VEGF levels associated with endometriosis in mice.


LXA4 may inhibit the progression of endometriosis possibly by anti-inflammation and anti-angiogenesis.